Sunday, August 24, 2014 5:25:36 AM
Pharming receives as a result of the acquisition access to five new product development, including for the treatment of Pompe disease, disease Farby and Gaucher disease. Pharming has access to knowledge regarding transgenic rabbits developed by TRM.
Pharming has deliberately chosen to take over. Only part of the activities of the French counterpart ,, Pharming is particularly interested in the developments related to the complex proteins, "confirmed CEO Sijmen de Vries, Pharming.,, We will be in Paris to continue looking for drugs for rare and life-threatening genetic diseases."
According to De Vries, it is too early to speak. Already possible results ,, We now further optimize research, "he.,, Continued Only after you decide on whether or not pre-clinical research and further steps. So really concrete results as a result of the acquisition to still take some time."
LEIDEN (AFN) - Het Leidse biotechnologiebedrijf Pharming neemt een aantal bezittingen over van de failliete Franse branchegenoot TRM SASU. Dat maakte het Leidse bedrijf dinsdag bekend. Met de koop is een bedrag van 500.000 euro gemoeid.
Pharming krijgt als gevolg van de acquisitie toegang tot vijf nieuwe productontwikkelingen, onder meer voor de behandeling van de ziekte van Pompe, de ziekte van Farby en de ziekte van Gaucher. Daarnaast heeft Pharming toegang gekregen tot kennis met betrekking tot transgene konijnen die is ontwikkeld door TRM.
Pharming heeft er bewust voor gekozen om slechts een deel van de activiteiten van de Franse branchegenoot over te nemen. ,,Pharming is vooral geïnteresseerd in de ontwikkelingen met betrekking tot de gecompliceerde eiwitten", bevestigde topman Sijmen de Vries van Pharming. ,,Wij zullen in Parijs verder zoeken naar medicijnen voor de zeldzame en levensbedreigende genetische ziekten."
Volgens De Vries is het te vroeg om al over eventuele resultaten te spreken. ,,Wij gaan nu onderzoek verder optimaliseren", vervolgde hij. ,,Pas daarna beslis je over al dan niet preklinisch onderzoek en verdere stappen. Dus echt concrete resultaten als gevolg van de overname laten nog wel even op zich wachten."
Recent PHARM News
- Pharming Group to participate in September investor conferences • GlobeNewswire Inc. • 09/04/2024 05:00:00 AM
- Pharming Group reports second quarter and first half 2024 financial results and provides business update • GlobeNewswire Inc. • 08/01/2024 05:00:00 AM
- Pharming Group to report second quarter and first half 2024 financial results on August 1 • GlobeNewswire Inc. • 07/18/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group to participate in June investor conferences • GlobeNewswire Inc. • 06/03/2024 06:00:00 AM
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union • GlobeNewswire Inc. • 05/30/2024 08:44:24 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 05/21/2024 03:30:14 PM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group to participate in May investor conference • GlobeNewswire Inc. • 05/20/2024 06:00:00 AM
- Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 05/15/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group reports first quarter 2024 financial results and provides business update • GlobeNewswire Inc. • 05/08/2024 05:00:00 AM
- Pharming Group to report first quarter 2024 financial results on May 8 • GlobeNewswire Inc. • 04/24/2024 06:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards • GlobeNewswire Inc. • 04/24/2024 05:00:00 AM
- Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/19/2024 04:43:36 PM
- Pharming Group announces the placement of €100 million convertible bonds due 2029 • GlobeNewswire Inc. • 04/18/2024 01:04:30 PM
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 • GlobeNewswire Inc. • 04/18/2024 06:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib • GlobeNewswire Inc. • 04/08/2024 05:00:00 AM
- Pharming Group announces the 2024 Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/04/2024 06:30:00 AM
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F • GlobeNewswire Inc. • 04/04/2024 05:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
- Pharming Group to participate in April investor conferences • GlobeNewswire Inc. • 04/03/2024 06:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM